test

Troy Wuertz

@Ikarian Capital, Llc

Latest period2024 - Q3ReportedManaged Assets$717.154MTotal holdings121
Assets growth rate24.93%Assets growth rate (2-Q avg)-6.06%Continuous growth in asset value1 quarters

Portfolio positions

This chart displays the top 10 holdings in Ikarian Capital, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 121 positions.

Assets under management

The assets under management (AUM) of Ikarian Capital, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 717.154M in assets, with a quarterly growth rate of 24.93% and a 2-quarter average growth rate of -6.06%. The portfolio is managed by Troy Wuertz, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
CRNXCrinetics Pharmaceuticals In
Recent Activity
Decreased -27.49%
3.05%
$21.815M
426,913 shares@ $51.11 avg price
SLNOSoleno Therapeutics Inc
Recent Activity
Decreased -25.59%
2.34%
$16.734M Call
331,437 shares@ $50.5 avg price
ELVNEnliven Therapeutics Inc
Recent Activity
Decreased -14.83%
1.78%
$12.759M
499,566 shares@ $25.54 avg price
CPRXCatalyst Pharmaceuticals Inc
Recent Activity
Decreased -19.39%
1.16%
$8.307M
417,850 shares@ $19.88 avg price
BBIOBridgebio Pharma Inc
Recent Activity
Decreased -15.5%
1.02%
$7.272M
285,613 shares@ $25.46 avg price
SRPTSarepta Therapeutics Inc
Recent Activity
Decreased -73.52%
0.95%
$6.766M
54,176 shares@ $124.9 avg price
NRIXNurix Therapeutics Inc
Recent Activity
Decreased -40.97%
0.82%
$5.842M
260,000 shares@ $22.47 avg price
NUVLNuvalent Inc
Recent Activity
Decreased -65.54%
0.75%
$5.344M
52,238 shares@ $102.3 avg price
PYXSPyxis Oncology Inc
Recent Activity
Decreased -21%
0.68%
$4.83M Call
1.316M shares@ $3.68 avg price
WVEWave Life Sciences Ltd
Recent Activity
Decreased -5.35%
0.63%
$4.463M
544,265 shares@ $8.2 avg price